Ernexa Therapeutics Inc. (ERNA)
Ernexa Therapeutics Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Ernexa Therapeutics Inc. (ERNA) is a Biotechnology company based in US with a market capitalization of $3.4M. Free cash flow was negative at -$7.1M. This page tracks ERNA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 6 employees · IPO Aug 29, 1991
Valuation
Valuation & price
$13.63as of May 17, 2026· -75.3% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
1.42
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$3.4M
Market cap
—
Revenue growth (YoY)
83.5%
Gross margin
-$7.1M
Free cash flow (USD)
-$1.4M
Net debt
Net cash position
-77.8%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2023 → 2024
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 11, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Ernexa Therapeutics Inc.'s market cap?
Ernexa Therapeutics Inc. (ERNA) has a market capitalization of $3.4M.
What is ERNA's P/E ratio?
A meaningful P/E ratio is not available for ERNA — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is ERNA's price-to-book (P/B) ratio?
ERNA trades at 1.42 times book value per share.
Are insiders buying ERNA stock?
SEC Form 4 filings show no open-market insider buys at Ernexa Therapeutics Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.